All In Biotech

NDA 050791 · Novartis

Myfortic

Mycophenolate Sodium · Oral

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Feb 27, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,244

230 Phase 3, 114 recruiting

FAERS reports

32,732

28,618 serious, 4,507 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY, MALIGNANCIES, AND SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)] . Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Myfortic. Patients receiving Myfortic should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions (5.2)] . Increased risk of development of lymphoma and other malignancies,...

What it is approved for

From the label in effect Jul 29, 2026.

Myfortic is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. ( 1.1 ) Use in combination with cyclosporine and corticosteroids. ( 1.1 ) Limitations of Use : Myfortic delayed-release tablets and mycophenolate mofetil tablets and capsules should not be used interchangeably. ( 1.2 ) 1.1 Prophylaxis of Organ Rejection in Kidney Transplant Myfortic ® (mycophenolic acid) is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. Myfortic is indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant. Myfortic is to be used in combination with cyclosporine and corticosteroids. 1.2 Limitations of Use Myfortic delayed-release tablets and mycophenolate mofetil (MMF) tablets and capsules should not be used interchangeably without physician supervision because the rate of absorption following the administration of these two products is not equivalent.

Mechanism: Mycophenolic acid (MPA), an immunosuppressant, is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways. MPA has cytostatic effects on lymphocytes. Mycophenolate sodium has been shown to prevent the occurrence of acute rejection in rat models of kidney and heart allotransplantation. Mycophenolate...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MYFORTIC · MYCOPHENOLATE SODIUM EQ 360MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
  • MYFORTIC · MYCOPHENOLATE SODIUM EQ 180MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mycophenolate" as an intervention, any sponsor and status, largest first.

All 1,244 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,957
  • diarrhoea2,043
  • drug ineffective1,894
  • death1,451
  • pyrexia1,363
  • acute kidney injury1,344
  • nausea1,239
  • fatigue1,076
  • covid-191,057
  • vomiting1,001
  • pneumonia997
  • headache990

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200425
200539
200682
2007123
2008216
2009268
2010362
2011615
2012629
2013624
2014822
20151,134
20161,324
20171,539
20181,831
20192,108
20202,641
20212,419
20222,959
20233,068
20243,608
20253,839
20262,456

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Myfortic (Mycophenolate Sodium)

2024 spending

$1.1M

Beneficiaries

182

756 claims

Per beneficiary

$5,809

$10.20 per unit

View as table
YearSpending
2020$2,373,206
2021$1,779,609
2022$1,476,491
2023$1,330,716
2024$1,057,200

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,271 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.